AMOXICILLIN AND CLAVULANATE POTASSIUM 250 mg/5mL; 62.5 mg/5mL For Suspension, 100 mL Bottle — NDC 81964-0204-10 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 81964-0204-10: AMOXICILLIN AND CLAVULANATE POTASSIUM 250 mg/5mL; 62.5 mg/5mL For Suspension, 100 mL Bottle

by USAntibiotics, LLC

This is a package of 100 mL of AMOXICILLIN AND CLAVULANATE POTASSIUM 250 mg/5mL; 62.5 mg/5mL For Suspension from USAntibiotics, LLC, first listed with the FDA Dec 2022 and currently FDA-listed; retail pharmacies pay about $0.4293 per mL (NADAC). It is the main listing for this product, which comes in 3 package sizes.

🏷️ FDA NDC (as labeled) 81964-204-10 billing pads the product segment with a zero
This package
Contains100 mL Cost per mL$0.4293 NADAC Per package$42.93 / 100 ml Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.4497/unit — full pricing hub ↓
Main listing for product 81964-204 · Also comes in: 75 ml 81964-204-07 150 ml 81964-204-15
Rx only Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Nov 12, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 81964-204-10 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
81964 labeler · 204 product · 10 package
Package marketed since
Dec 5, 2022
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
100 mL per package
Barcode (UPC)
0381964221145, 0381964212037, 0381964212051
Medicaid fills, this package
5,706 prescriptions in the last four reported quarters
FDA record last changed
Nov 12, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 81964-204-10
Product NDC 81964-204
11-digit billing NDC 81964020410
NCPDP billing unit ML — per mL (volume)
RxCUI 562508, 617302, 617322
UNII Q42OMW3AT8, 804826J2HU
UPC 0381964221145, 0381964212037, 0381964212051
Application # NDA050575
SPL Set ID c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3
Established class (EPC) Penicillin-class Antibacterial; beta Lactamase Inhibitor
Mechanism of action beta Lactamase Inhibitors
Chemical class Penicillins
DEA schedule Non-controlled
Marketing category NDA AUTHORIZED GENERIC
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2022-12-05
Route ORAL
Dosage form FOR SUSPENSION
Substance AMOXICILLIN; CLAVULANATE POTASSIUM
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 008990
GCN 67151
HICL code 003962
Ingredient (HICL) Amoxicillin/Potassium Clavulanate
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W1
Therapeutic class — intermediate (HIC2) Antibiotics
HIC3 code W1A
Therapeutic class — specific (HIC3) Penicillin Antibiotics
AHFS code 08:12.16.08
AHFS class Aminopenicillin Antibiotics
FDB label name AMOX-CLAV 250-62.5 MG/5 ML SUS
FDB brand name Amoxicillin-Clavulanate Potass
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 008990
  • GCN: 67151
  • HICL (First Databank): 003962
  • AHFS class code: 08:12.16.08
  • RxCUI (RxNorm): 562508
Why two NDCs? The FDA registers this code as 81964-204-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 81964-0204-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Penicillins with extended spectrum class.

Drug family (ATC) Penicillins with extended spectrum
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name AMOX-CLAV 250-62.5 MG/5 ML SUS Ingredient Amoxicillin/Potassium Clavulanate
📖 What it is MedlinePlus · NLM

Amoxicillin and clavulanic acid is used to treat certain infections caused by bacteria, including infections of the ears, lungs, sinus, skin, and urinary tract. Amoxicillin is in a class of medications called penicillin-like antibiotics. It works by stopping the growth of bacteria. Clavulanic acid is in a class of medications called beta-lactamase inhibitors. It works by stopping bacteria from breaking down amoxicillin. Antibiotics will not work for colds, flu, or other viral infections. Using antibiotics when they are not needed increases your risk of getting an infection later that resists a...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats bacterial infections such as ear, sinus, lung, skin and urinary tract infections when the bacteria make beta-lactamase. It does not work for viral illnesses like colds or...
  • What is Amoxicillin / Clavulanate used for?
  • You can take it with or without food. Taking it at the start of a meal helps you absorb the clavulanate and can lessen stomach upset, so I usually suggest that.
  • Should I take Amoxicillin / Clavulanate with food?
📖 Read our full Amoxicillin / Clavulanate guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.429 $42.93 / 100 ml
Medicaid paysCMS SDUD · 12 mo $0.4497 $44.97 / 100 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2024 Jul 2025 Mar 2026 Nov 2026 $0.479 $0.392
▼ Down 5% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
81964-0204-07 81964-204-07 75 mL in 1 BOTTLE $0.4102 / mL $30.77 2022-12-05 — Active
81964-0204-10 You're viewing this Main listing 100 mL in 1 BOTTLE $0.4293 / mL $42.93 2022-12-05 — Active
81964-0204-15 81964-204-15 150 mL in 1 BOTTLE $0.4119 / mL $61.78 2022-12-05 — Active

You're viewing one of 3 pack sizes for this product.

Per mL, this pack runs about 5% above the cheapest pack (75 mL, $0.4102 vs $0.4293 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 55% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 100 mL — 100 ml in 1 bottle.
How does this package differ from NDC 81964-0204-07?
Both are AMOXICILLIN AND CLAVULANATE POTASSIUM 250 mg/5mL; 62.5 mg/5mL For Suspension — the drug itself is identical. This page's package is the 100 mL one, while NDC 81964-0204-07 is the 75 ml package. Per-mL NADAC also differs: $0.4293 here vs $0.4102 for the 75 ml pack.
What NDC number is used to bill for this package of AMOXICILLIN AND CLAVULANATE POTASSIUM 250 mg/5mL; 62.5 mg/5mL For Suspension?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
amoxicillin and clavulanate potassium 250 mg/5mL; 62.5 mg/5mL 73043-0010-01 Devatis, 75 ml $0.410 AB Availability likely save 4%
Amoxicillin and Clavulanate potassium 250 mg/5mL; 62.5 mg/5mL 69097-0098-08 Cipla 150 ml $0.412 AB Availability likely save 4%
Amoxicillin and Clavulanate Potassium 250 mg/5mL; 62.5 mg/5mL 59651-0026-01 Aurobindo 100 ml $0.429 AB Availability likely —
Amoxicillin And Clavulanate Potassium 250 mg/5mL; 62.5 mg/5mLthis 81964-0204-10 USAntibiotics, 100 ml $0.429 AB Availability likely —
About this product: this is an authorized generic — the brand-name product marketed without its brand name. Other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
Listed with the FDA since
Dec 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeCapsule
ImprintAUGMENTIN;875
Size18 mm
ScoringScored — splits in 2
FlavorOrange
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Amoxicillin / Clavulanate inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3OWL53L36A
    A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
  • UNII SB8ZUX40TY
    Saccharin sodium is an artificial sweetener made from saccharin salt. It's added to medicines to improve taste, especially in liquid formulations for children or bitter drugs.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII AB6MNQ6J6L
    Succinic acid is an organic acid derived from natural sources or chemical synthesis. In medications, it functions as a buffer to help maintain the proper pH level and may also serve as a preservative or flavor enhancer in formulations.
  • UNII TTV12P4NEE
    Xanthan gum is a thickening and stabilizing ingredient made from fermented corn or other sugars. It's added to medicines to improve texture, prevent separation of liquids and solids, and help the product stay consistent.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerUSAntibiotics, LLC
Application holderUS ANTIBIOTICS LLC
FDA applicationNDA050575 (NDA AUTHORIZED GENERIC)
Labeler code81964
First marketedDec 2022
Product typeHuman Prescription Drug
Portfolio11 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ~2 min read ▾

1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis .

Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections Limitations of Use When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, Amoxicillin and Clavulanate Potassium should not be used.

( 1 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium and other antibacterial drugs, Amoxicillin and Clavulanate Potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1 ) Limitations of Use When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, Amoxicillin and Clavulanate Potassium should not be used. Usage To reduce the development of drug‑resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium and other antibacterial drugs, Amoxicillin and Clavulanate Potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION Adults and Pediatric Patients greater than 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours, based on the amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component.

Use of the 125 mg/5 mL oral suspension is recommended. ( 2.3 )

2.1Important Administration Instructions Amoxicillin and Clavulanate Potassium may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when Amoxicillin and Clavulanate Potassium is administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, Amoxicillin and Clavulanate Potassium should be taken at the start of a meal.

2.2Adult Patients See dosing regimens of Amoxicillin and Clavulanate Potassium (based on the amoxicillin component) provided in Table 1 below. Table 1. Dosing Regimens of Amoxicillin and Clavulanate Potassium in Adult Patients TYPE OF INFECTION DOSING REGIMEN OF Amoxicillin and Clavulanate Potassium Severe infections and infections of the respiratory tract one 875 mg tablet a of Amoxicillin and Clavulanate Potassium every 12 hours or one 500 mg tablet b,c of Amoxicillin and Clavulanate Potassium every 8 hours Less severe infections one 500 mg tablet b,c of Amoxicillin and Clavulanate Potassium every 12 hours or one 250 mg tablet d of Amoxicillin and Clavulanate Potassium every 8 hours a Adults who have difficulty swallowing may be given the Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL suspension or the Amoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL suspension may be used in place of the 875 mg/125 mg tablet. b Adults who have difficulty swallowing may be given the Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL or Amoxicillin and Clavulanate Potassium 250 mg/62.5 mg per 5 mL suspension in place of the 500 mg/125 mg tablet. c Two Amoxicillin and Clavulanate Potassium 250 mg/125 mg tablets are NOT substitutable with one 500 mg/125 mg Amoxicillin and Clavulanate Potassium tablet [see Dosage and Administration ( 2.6 )] . d Amoxicillin and Clavulanate Potassium 250 mg/125 mg tablet is NOT substitutable with Amoxicillin and Clavulanate Potassium 250 mg/62.5 mg chewable tablet [see Dosage and Administration ( 2.6 )]

2.3Pediatric Patients Based on the amoxicillin component, Amoxicillin and Clavulanate Potassium should be dosed as follows: Neonates and Infants Aged less than 12 weeks (less than 3 months) : See dosing regimens of Amoxicillin and Clavulanate Potassium provided in Table 2 below. Table 2: Dosing Regimens of Amoxicillin and Clavulanate Potassium in Neonates and Infants Aged Less than 12 Weeks (Less than 3 Months) PATIENT POPULATION DOSING REGIMEN Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL for oral suspension a Neonates and Infants aged less than 12 weeks (less than 3 months) 30 mg/kg/day every 12 hours a Experience with the Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL formulation in this age group is limited, and thus, use of the Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL for oral suspension is recommended.

Patients Aged 12 weeks (3 months) and Older and Weighing Less than 40 kg : See dosing regimens provided in Table 3 below. The every 12 hour regimen is recommended as it is associated with significantly less diarrhea [see Clinical Studies ( 14.2 )] . The Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL and Amoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL) for oral suspension and Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg and Amoxicillin and Clavulanate Potassium 400 mg/57 mg chewable tablets contain aspartame and should not be used by phenylketonurics. [see Warnings and Precautio… [Excerpted — this section continues on DailyMed.]

💊 Dosage Forms and Strengths ~2 min read ▾

3 DOSAGE FORMS AND STRENGTHS Amoxicillin and Clavulanate Potassium Tabl ets, USP : 250 mg/125 mg Tablets: Each white oval film-coated tablet, debossed with AUGMENTIN on one side and 250/125 on the other side, contains 250 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt. 500 mg/125 mg Tablets : Each white oval film-coated tablet, debossed with AUGMENTIN on one side and 500/125 on the other side, contains 500 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt.

875 mg/125 mg Tablets : Each scored white capsule‑shaped tablet, debossed with AUGMENTIN 875 on one side and scored on the other side, contains 875 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt. Amoxicillin and Clavulanate Potassium for Oral Suspension, USP: 125 mg/31.25 mg per 5 mL : Banana-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 125 mg of amoxicillin as the trihydrate and 31.25 mg of clavulanic acid as the potassium salt). 200 mg/28.5 mg per 5 mL : Orange-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 200 mg of amoxicillin as the trihydrate and 28.5 mg of clavulanic acid as the potassium salt).

250 mg/62.5 mg per 5 mL : Orange-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 250 mg of amoxicillin as the trihydrate and 62.5 mg of clavulanic acid as the potassium salt). 400 mg/57 mg per 5 mL: Orange-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 400 mg of amoxicillin as the trihydrate and 57 mg of clavulanic acid as the potassium salt). Amoxicillin and Clavulanate Potassium Chewable Tablets, USP: 125 mg/31.25 mg Chewable Tablets : Each mottled yellow, round, lemon-lime-flavored tablet, debossed with BMP 189 contains 125 mg of amoxicillin as the trihydrate and 31.25 mg of clavulanic acid as the potassium salt.

200 mg/28.5 mg Chewable Tablets : Each mottled pink, round, biconvex cherry-banana-flavored tablet, debossed with AUGMENTIN 200 contains 200 mg of amoxicillin as the trihydrate and 28.5 mg of clavulanic acid as the potassium salt. 250 mg/62.5 mg Chewable Tablets : Each mottled yellow, round, lemon-lime-flavored tablet, debossed with BMP 190 contains 250 mg of amoxicillin as the trihydrate and 62.5 mg of clavulanic acid as the potassium salt. 400 mg/57 mg Chewable Tablets : Each mottled pink, round, biconvex cherry-banana-flavored tablet, debossed with AUGMENTIN 400 contains 400 mg of amoxicillin as the trihydrate and 57 of clavulanic acid as the potassium salt.

Tablets: 250 mg/125 mg, 500 mg/125 mg, 875 mg/125 mg; 875 mg/125 mg tablets are scored. ( 3 ) For Oral Suspension: 125 mg/31.25 mg per 5 mL, 200 mg/28.5 mg per 5 mL, 250 mg/62.5 mg per 5 mL, 400 mg/57 mg per 5 mL ( 3 ) Chewable Tablets: 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg, 400 mg/57 mg ( 3 )

⛔ Contraindications 106 words ▾

4 CONTRAINDICATIONS History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to Amoxicillin and Clavulanate Potassium or to other beta‑lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with Amoxicillin and Clavulanate Potassium. ( 4.2 )

4.1Serious Hypersensitivity Reactions Amoxicillin and Clavulanate Potassium is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin, clavulanate or to other beta‑lactam antibacterial drugs (e.g., penicillins and cephalosporins).

4.2Cholestatic Jaundice/Hepatic Dysfunction Amoxicillin and Clavulanate Potassium is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with Amoxicillin and Clavulanate Potassium.

⚠️ Warnings and Cautions ~2 min read ▾

5 WARNINGS AND PRECAUTIONS Serious (including fatal) hypersensitivity reactions: Discontinue Amoxicillin and Clavulanate Potassium if a reaction occurs. ( 5.1 ) Severe Cutaneous Adverse Reactions (SCAR): Monitor closely. Discontinue if rash progresses.

( 5.2 ) Drug-induced enterocolitis syndrome (DIES) has been reported with use of amoxicillin, a component of Amoxicillin and Clavulanate Potassium. If this occurs, discontinue Amoxicillin and Clavulanate Potassium and institute appropriate therapy. ( 5.3 ) Hepatic dysfunction and cholestatic jaundice: Discontinue if signs/symptoms of hepatitis occur.

Monitor liver function tests in patients with hepatic impairment. ( 5.4 ) Clostridioides difficile -associated diarrhea (CDAD): Evaluate patients if diarrhea occurs. ( 5.5 ) Patients with mononucleosis who receive Amoxicillin and Clavulanate Potassium develop skin rash.

Avoid Amoxicillin and Clavulanate Potassium use in these patients. ( 5.6 ) Overgrowth: The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. ( 5.7 )

5.1Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterials, including Amoxicillin and Clavulanate Potassium. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. Before initiating therapy with Amoxicillin and Clavulanate Potassium, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens.

If an allergic reaction occurs, Amoxicillin and Clavulanate Potassium should be discontinued, and appropriate therapy instituted.

5.2Severe Cutaneous Adverse Reactions Amoxicillin and Clavulanate Potassium may cause severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). If patients develop a skin rash, they should be monitored closely, and Amoxicillin and Clavulanate Potassium discontinued if lesions progress.

5.3Drug-Induced Enterocolitis Syndrome (DIES) Drug-induced enterocolitis syndrome (DIES) has been reported with use of amoxicillin, a component of Amoxicillin and Clavulanate Potassium [see Adverse Reactions (6.2)] , with most cases occurring in pediatric patients ≤ 18 years of age. DIES is a non-IgE mediated hypersensitivity reaction characterized by protracted vomiting occurring 1 to 4 hours after drug ingestion in the absence of skin or respiratory symptoms. DIES may be associated with pallor, lethargy, hypotension, shock, diarrhea within 24 hours after ingesting amoxicillin, and leukocytosis with neutrophilia.

If DIES occurs, discontinue Amoxicillin and Clavulanate Potassium and institute appropriate therapy.

5.4Hepatic Dysfunction Hepatic dysfunction, including hepatitis and cholestatic jaundice has been associated with the use of Amoxicillin and Clavulanate Potassium. Hepatic toxicity is usually reversible; however, deaths have been reported. Hepatic function should be monitored at regular intervals in patients with hepatic impairment.

5.5Clostridioides difficile Associated Diarrhea (CDAD) Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Amoxicillin and Clavulanate Potassium, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD.

Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all pat… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling: Anaphylactic reactions [see Warnings and Precautions (5.1) ] Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.2 )] Drug-Induced Enterocolitis Syndrome (DIES) [see Warning and Precautions ( 5.3 )] Hepatic Dysfunction [see Warnings and Precautions (5.4) ] Clostridioides difficile Associated Diarrhea (CDAD) [see Warnings and Precautions (5.5) ] The most frequently reported adverse effects were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%).

( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact USAntibiotics, LLC at 1-844-454-5532 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

6.1Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported adverse reactions were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%). Less than 3% of patients discontinued therapy because of drug‑related adverse reactions.

The overall incidence of adverse reactions, and in particular diarrhea, increased with the higher recommended dose. Other less frequently reported adverse reactions (less than 1%) include: Abdominal discomfort, flatulence, and headache. In pediatric patients (aged 2 months to 12 years), 1 US/Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of Amoxicillin and Clavulanate Potassium for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of Amoxicillin and Clavulanate Potassium for 10 days in the treatment of acute otitis media.

A total of 575 patients were enrolled, and only the suspension formulations were used in this trial. Overall, the adverse reactions seen were comparable to that noted above; however, there were differences in the rates of diarrhea, skin rashes/urticaria, and diaper area rashes. [see Clinical Studies ( 14.2 )] .

6.2Postmarketing Experience In addition to adverse reactions reported from clinical trials, the following have been identified during postmarketing use of Amoxicillin and Clavulanate Potassium. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to Amoxicillin and Clavulanate Potassium.

Gastrointestinal: Drug-induced enterocolitis syndrome (DIES), indigestion, gastritis, stomatitis, glossitis, black “hairy” tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. [see Warnings and Precautions ( 5.5 )] . Immune: Hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock), angioedema, serum sickness-like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia, and frequently fever), hypersensitivity vasculitis [see Warnings and Precautions ( 5.1 )] .

Skin and Appendages: Rashes, pruritus, urticaria, erythema multiforme, SJS, TEN, DRESS, AGEP, exfoliative dermatitis, and linear IgA bullous dermatosis. Liver: Hepatic dysfunction, including hepatitis and cholestatic jaundice, increases in serum transaminases (AST and/or ALT), serum bilirubin, and/or alkaline phosphatase, has been reported with Amoxicillin and Clavulanate Potassium. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment.

The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic hepatocellular changes. The onset of signs/symptoms of h… [Excerpted — this section continues on DailyMed.]

🔄 Drug Interactions ~1 min read ▾

7 DRUG INTERACTIONS Co‑administration with probenecid is not recommended. ( 7.1 ) Concomitant use of Amoxicillin and Clavulanate Potassium and oral anticoagulants may increase the prolongation of prothrombin time.( 7.2 ) Co-administration with allopurinol increases the risk of rash. ( 7.3 ) Amoxicillin and Clavulanate Potassium may reduce efficacy of oral contraceptives. ( 7.4 )

7.1Probenecid Probenecid decreases the renal tubular secretion of amoxicillin but does not delay renal excretion of clavulanic acid. Concurrent use with Amoxicillin and Clavulanate Potassium may result in increased and prolonged blood concentrations of amoxicillin. Co-administration of probenecid is not recommended.

7.2Oral Anticoagulants Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently with Amoxicillin and Clavulanate Potassium. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.

7.3Allopurinol The concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients.

7.4Oral Contraceptives Amoxicillin and Clavulanate Potassium may affect intestinal flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

7.5Effects on Laboratory Tests High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST ® , Benedict's Solution, or Fehling's Solution. Since this effect may also occur with Amoxicillin and Clavulanate Potassium, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be used. Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS Pediatric Use: Modify dose in patients 12 weeks or younger. ( 8.4 ) Renal Impairment: Dosage adjustment is recommended for severe renal impairment (GFR less than 30mL/min). ( 2.4 , 8.6 )

8.1Pregnancy Teratogenic Effects : Pregnancy Category B. Reproduction studies performed in pregnant rats and mice given Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to Amoxicillin and Clavulanate Potassium. The amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg every 12 hours).

For clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

8.2Labor and Delivery Oral ampicillin‑class antibacterials are poorly absorbed during labor. It is not known whether use of amoxicillin and clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention.

8.3Nursing Mothers Amoxicillin has been shown to be excreted in human milk. Amoxicillin and clavulanate potassium use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman.

8.4Pediatric Use The safety and effectiveness of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets have been established in pediatric patients. Use of Amoxicillin and Clavulanate Potassium in pediatric patients is supported by evidence from studies of Amoxicillin and Clavulanate Potassium Tablets in adults with additional data from a study of Amoxicillin and Clavulanate Potassium for Oral Suspension in pediatric patients aged 2 months to 12 years with acute otitis media [see Clinical Studies ( 14.2 )] .

Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed; clavulanate elimination is unaltered in this age group. Dosing of Amoxicillin and Clavulanate Potassium should be modified in pediatric patients aged less than 12 weeks (less than 3 months) [see Dosage and Administration ( 2.3 )].

8.5Geriatric Use Of the 3,119 patients in an analysis of clinical studies of Amoxicillin and Clavulanate Potassium, 32% were greater than or equal to 65 years old, and 14% were greater than or equal to 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

8.6Renal Impairment Amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (GFR less than 30 mL/min). See Patients with Renal Impairment [see Dosage and Administration ( 2.4 )] for specific recommendations in patients with renal impairment.

🤰 Pregnancy 133 words ▾

8.1Pregnancy Teratogenic Effects : Pregnancy Category B. Reproduction studies performed in pregnant rats and mice given Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to Amoxicillin and Clavulanate Potassium. The amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg every 12 hours).

For clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

🧒 Pediatric Use 135 words ▾

8.4Pediatric Use The safety and effectiveness of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets have been established in pediatric patients. Use of Amoxicillin and Clavulanate Potassium in pediatric patients is supported by evidence from studies of Amoxicillin and Clavulanate Potassium Tablets in adults with additional data from a study of Amoxicillin and Clavulanate Potassium for Oral Suspension in pediatric patients aged 2 months to 12 years with acute otitis media [see Clinical Studies ( 14.2 )] .

Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed; clavulanate elimination is unaltered in this age group. Dosing of Amoxicillin and Clavulanate Potassium should be modified in pediatric patients aged less than 12 weeks (less than 3 months) [see Dosage and Administration ( 2.3 )].

🧓 Geriatric Use 138 words ▾

8.5Geriatric Use Of the 3,119 patients in an analysis of clinical studies of Amoxicillin and Clavulanate Potassium, 32% were greater than or equal to 65 years old, and 14% were greater than or equal to 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

🆘 Overdosage 163 words ▾

10 OVERDOSAGE In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms 1 . Interstitial nephritis resulting in oliguric renal failure has been reported in patients after overdosage with amoxicillin and clavulanate potassium.

Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin and clavulanate potassium overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin and clavulanate potassium crystalluria. Renal impairment appears to be reversible with cessation of drug administration.

High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin and clavulanate potassium. Amoxicillin and clavulanate potassium may be removed from circulation by hemodialysis [see Dosage and Administration ( 2.4 )] .

🧬 Clinical Pharmacology ~3 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Amoxicillin and Clavulanate Potassium is an antibacterial drug [see Microbiology ( 12.4 )] .

12.3Pharmacokinetics Mean amoxicillin and clavulanate potassium pharmacokinetic parameters in normal adults following administration of Amoxicillin and Clavulanate Potassium Tablets are shown in Table 6 and following administration of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets are shown in Table 7. Table 6: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium Tablets a Mean (± standard deviation) values of 14 normal adults (N equals15 for clavulanate potassium in the low-dose regimens).

Peak concentrations occurred approximately 1.5 hours after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose and Regimen of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 250 mg/125 mg every 8 hours 3.3 ± 1.12 1.5 ± 0.70 26.7 ± 4.56 12.6 ± 3.25 500 mg/125 mg every 12 hours 6.5 ± 1.41 1.8 ± 0.61 33.4 ± 6.76 8.6 ± 1.95 500 mg/125 mg every 8 hours 7.2 ± 2.26 2.4 ± 0.83 53.4 ± 8.87 15.7 ± 3.86 875 mg/125 mg every 12 hours 11.6 ± 2.78 2.2 ± 0.99 53.5 ± 12.31 10.2 ±

3.04Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets a Mean (± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 400 mg/57 mg (5 mL of suspension) 6.94 ± 1.24 1.10 ± 0.42 17.29 ± 2.28 2.34 ± 0.94 400 mg/57 mg (1 chewable tablet) 6.67 ± 1.37 1.03 ± 0.33 17.24 ± 2.64 2.17 ±

0.73Oral administration of 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or the equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium provides average peak serum concentrations approximately 1 hour after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid. The areas under the serum concentration curves obtained during the first 4 hours after dosing were 12.6 mcg*h/mL for amoxicillin and 2.9 mcg*h/mL for clavulanic acid when 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium were administered to normal adults.

One 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium or two 125 mg/31.25 mg chewable tablets of Amoxicillin and Clavulanate Potassium are equivalent to 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium and provide similar serum concentrations of amoxicillin and clavulanic acid. Amoxicillin serum concentrations achieved with Amoxicillin and Clavulanate Potassium are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. Time above the minimum inhibitory concentration of 1 mcg/mL for amoxicillin has been shown to be similar after corresponding every 12 hour and every 8-hour dosing regimens of Amoxicillin and Clavulanate Potassium in adults and children.

Absorption : Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While Amoxicillin and Clavulanate Potassium can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In one study, the relative bioavailability of clavulanate was reduced when Amoxicillin and Clavulanate Potassium… [Excerpted — this section continues on DailyMed.]

🧬 Mechanism of Action 18 words ▾

12.1Mechanism of Action Amoxicillin and Clavulanate Potassium is an antibacterial drug [see Microbiology ( 12.4 )] .

📦 How Supplied / Storage and Handling ~3 min read ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Amoxicillin and Clavulanate Potassium Tablets, USP: 250 mg/125 mg Tablets : Each white oval film-coated tablet, debossed with AUGMENTIN on one side and 250/125 on the other side, contains 250 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt (equivalent to 149 mg of clavulanate potassium). 81964-218-30 bottles of 30 81964-218-70 Unit Dose (10x10) 100 tablets 500 mg/125 mg Tablets : Each white oval film-coated tablet, debossed with AUGMENTIN on one side and 500/125 on the other side, contains 500 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt (equivalent to 149 mg of clavulanate potassium).

NDC 81964-206-14 bottles of 20 NDC 81964-206-78 Unit Dose (10x10) 100 tablets 875 mg/125 mg Tablets : Each scored white capsule-shaped tablet, debossed with Augmentin 875 on one side and scored on the other side, contains 875 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt (equivalent to 149 mg of clavulanate potassium). NDC 81964-221-14 bottles of 20 NDC 81964-221-78 Unit Dose (10x10) 100 tablets NDC 81964-221-01 bottles of 100 Amoxicillin and Clavulanate Potassium for Oral Suspension, USP : 125 mg/31.25 mg per 5 mL : Banana-flavored powder for oral suspension, each 5 mL of reconstituted suspension contains 125 mg of amoxicillin as the trihydrate and 31.25 mg of clavulanic acid as the potassium salt (equivalent to 37.23 mg of clavulanate potassium).

NDC 81964-212-01 75 mL bottle NDC 81964-212-03 100 mL bottle NDC 81964-212-05 150 mL bottle 200 mg/28.5 mg per 5 mL : Orange-flavored powder for oral suspension, each 5 mL of reconstituted suspension contains 200 mg of amoxicillin as the trihydrate and 28.5 mg of clavulanic acid as the potassium salt (equivalent to 34 mg of clavulanate potassium). NDC 81964-213-50 50 mL bottle NDC 81964-213-51 75 mL bottle NDC 81964-213-52 100 mL bottle 250 mg/62.5 mg per 5 mL : Orange-flavored powder for oral suspension, each 5 mL of reconstituted suspension contains 250 mg of amoxicillin as the trihydrate and 62.5 mg of clavulanic acid as the potassium salt (equivalent to 74.5 mg of clavulanate potassium).

NDC 81964-204-07 75 mL bottle NDC 81964-204-10 100 mL bottle NDC 81964-204-15 150 mL bottle 400 mg/57 mg per 5 mL Orange-flavored powder for oral suspension, each 5 mL of reconstituted suspension contains 400 mg of amoxicillin as the trihydrate and 57 mg of clavulanic acid as the potassium salt (equivalent to 68 mg of clavulanate potassium). NDC 81964-208-50 50 mL bottle NDC 81964-208-51 75 mL bottle NDC 81964-208-52 100 mL bottle Amoxicillin and Clavulanate Potassium Chewable Tablets, USP : 125 mg/31.25 mg Chewable Tablets : Each mottled yellow, round, lemon-lime-flavored tablet, debossed with BMP 189, contains 125 mg of amoxicillin as the trihydrate and 31.25 mg clavulanic acid as the potassium salt (equivalent to 37.23 mg of clavulanate potassium).

NDC 81964-214-31 Unit Dose (5x6) 30 chewable tablets 200 mg/28.5 mg Chewable Tablets : Each mottled pink, round, biconvex, cherry-banana-flavored tablet, debossed with AUGMENTIN 200, contains 200 mg of amoxicillin as the trihydrate and 28.5 mg clavulanic acid as the potassium salt (equivalent to 34 mg of clavulanate potassium). NDC 81964-215-14 Unit Dose (4x5) 20 chewable tablets 250 mg/62.5 mg Chewable Tablets : Each mottled yellow, round, lemon-lime-flavored tablet, debossed with BMP 190, contains 250 mg of amoxicillin as the trihydrate and 62.5 mg clavulanic acid as the potassium salt (equivalent to 74.5 mg of clavulanate potassium).

NDC 81964-216-31 Unit Dose (5x6) 30 chewable tablets 400 mg/57 mg Chewable Tablets : Each mottled pink, round, biconvex, cherry-banana-flavored tablet, debossed with AUGMENTIN 400, contains 400 mg of amoxicillin as the trihydrate and 57 mg clavulanic acid as the potassium salt (equivalent to 68 mg of clavulanate potassium). NDC 81964-217-14 Unit Dose (4x5) 20 chewable tablets… [Excerpted — this section continues on DailyMed.]

📋 Description ~3 min read ▾

11 DESCRIPTION Amoxicillin and Clavulanate Potassium is an oral antibacterial combination consisting of amoxicillin and the beta‑lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6‑aminopenicillanic acid. The amoxicillin molecular formula is C 16 H 19 N 3 O 5 S•3H 2 O, and the molecular weight is 419.46.

Chemically, amoxicillin is (2 S ,5 R ,6 R )-6-[( R )-(-)-2-Amino-2-( p -hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and may be represented structurally as: Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus . It is a beta-lactam structurally related to the penicillins and possesses the ability to inactivate some beta‑lactamases by blocking the active sites of these enzymes. The clavulanate potassium molecular formula is C 8 H 8 KNO 5 , and the molecular weight is 237.25.

Chemically, clavulanate potassium is potassium ( Z )(2 R ,5 R )-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate and may be represented structurally as: Amoxicillin and Clavulanate Potassium Tablets: 250 mg/125 mg: Each tablet contains 250 mg of amoxicillin as the trihydrate, and 125 mg of clavulanic acid (equivalent to 149 mg of clavulanate potassium). 500 mg/125 mg: Each tablet contains 500 mg of amoxicillin as the trihydrate, and 125 mg of clavulanic acid (equivalent to 149 mg of clavulanate potassium).

875 mg/125 mg: Each tablet contains 875 mg of amoxicillin as the trihydrate, and 125 mg of clavulanic acid (equivalent to 149 mg of clavulanate potassium). Amoxicillin and Clavulanate Potassium for Oral Suspension: 125 mg/31.25 mg : Following constitution, each 5 mL of oral suspension contains 125 mg of amoxicillin as the trihydrate, and 31.25 mg of clavulanic acid (equivalent to 37.23 mg of clavulanate potassium). 200 mg/28.5 mg : Following constitution, each 5 mL of oral suspension contains 200 mg of amoxicillin as the trihydrate, and 28.5 mg of clavulanic acid (equivalent to 34 mg of clavulanate potassium).

250 mg/62.5 mg : Following constitution, each 5 mL of oral suspension contains 250 mg of amoxicillin as the trihydrate, and 62.5 mg of clavulanic acid (equivalent to 74.5 mg of clavulanate potassium). 400 mg/57 mg : Following constitution, each 5 mL of oral suspension contains 400 mg of amoxicillin as the trihydrate, and 57 mg of clavulanic acid (equivalent to 68 mg of clavulanate potassium). Amoxicillin and Clavulanate Potassium Chewable Tablets: 125 mg/31.25 mg: Each chewable tablet contains 125 mg of amoxicillin as the trihydrate, and 31.25 mg of clavulanic acid (equivalent to 37.23 mg of clavulanate potassium).

200 mg/28.5 mg: Each chewable tablet contains 200 mg of amoxicillin as the trihydrate, and 28.5 mg of clavulanic acid (equivalent to 34 mg of clavulanate potassium). 250 mg/62.5 mg: Each chewable tablet contains 250 mg of amoxicillin as the trihydrate, and 62.5 mg of clavulanic acid (equivalent to 74.5 mg of clavulanate potassium). 400 mg/57 mg: Each chewable tablet contains 400 mg of amoxicillin as the trihydrate, and 57 mg of clavulanic acid (equivalent to 68 mg of clavulanate potassium).

Inactive Ingredients: Amoxicillin and Clavulanate Potassium Tablets - Colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide. • Each tablet of Amoxicillin and Clavulanate Potassium contains 0.63 mEq potassium. Amoxicillin and Clavulanate Potassium for Oral Suspension, 125 mg/31.5 mg per 5mL and 250 mg/62.5 mg per 5mL - Colloidal silicon dioxide, flavorings, xanthan gum, mannitol, succinic acid, silica gel and sodium saccharin. • Each 5 mL of reconstituted 125 mg/31.5 mg oral suspension of Amoxicillin and Clavulanate Potassium contains 0.16 mEq potassium • Each 5 mL of reconstituted 250 mg/62.5 mg oral suspension of Amoxicilli… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 42 words ▾

8.3Nursing Mothers Amoxicillin has been shown to be excreted in human milk. Amoxicillin and clavulanate potassium use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman.

🧬 Pharmacokinetics ~3 min read ▾

12.3Pharmacokinetics Mean amoxicillin and clavulanate potassium pharmacokinetic parameters in normal adults following administration of Amoxicillin and Clavulanate Potassium Tablets are shown in Table 6 and following administration of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets are shown in Table 7. Table 6: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium Tablets a Mean (± standard deviation) values of 14 normal adults (N equals15 for clavulanate potassium in the low-dose regimens).

Peak concentrations occurred approximately 1.5 hours after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose and Regimen of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 250 mg/125 mg every 8 hours 3.3 ± 1.12 1.5 ± 0.70 26.7 ± 4.56 12.6 ± 3.25 500 mg/125 mg every 12 hours 6.5 ± 1.41 1.8 ± 0.61 33.4 ± 6.76 8.6 ± 1.95 500 mg/125 mg every 8 hours 7.2 ± 2.26 2.4 ± 0.83 53.4 ± 8.87 15.7 ± 3.86 875 mg/125 mg every 12 hours 11.6 ± 2.78 2.2 ± 0.99 53.5 ± 12.31 10.2 ±

3.04Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets a Mean (± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 400 mg/57 mg (5 mL of suspension) 6.94 ± 1.24 1.10 ± 0.42 17.29 ± 2.28 2.34 ± 0.94 400 mg/57 mg (1 chewable tablet) 6.67 ± 1.37 1.03 ± 0.33 17.24 ± 2.64 2.17 ±

0.73Oral administration of 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or the equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium provides average peak serum concentrations approximately 1 hour after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid. The areas under the serum concentration curves obtained during the first 4 hours after dosing were 12.6 mcg*h/mL for amoxicillin and 2.9 mcg*h/mL for clavulanic acid when 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium were administered to normal adults.

One 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium or two 125 mg/31.25 mg chewable tablets of Amoxicillin and Clavulanate Potassium are equivalent to 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium and provide similar serum concentrations of amoxicillin and clavulanic acid. Amoxicillin serum concentrations achieved with Amoxicillin and Clavulanate Potassium are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. Time above the minimum inhibitory concentration of 1 mcg/mL for amoxicillin has been shown to be similar after corresponding every 12 hour and every 8-hour dosing regimens of Amoxicillin and Clavulanate Potassium in adults and children.

Absorption : Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While Amoxicillin and Clavulanate Potassium can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In one study, the relative bioavailability of clavulanate was reduced when Amoxicillin and Clavulanate Potassium was dosed at 30 and 150 minutes after the start of a high‑fat breakfast.

Distribution : Neither component in Amoxicillin and Clavulanate Potass… [Excerpted — this section continues on DailyMed.]

🔬 Clinical Studies ~3 min read ▾

14 CLINICAL STUDIES

14.1Lower Respiratory Tract and Complicated Urinary Tract Infections Data from 2 pivotal trials in 1,191 patients treated for either lower respiratory tract infections or complicated urinary tract infections compared a regimen of 875 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium every 12 hours to 500 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium dosed every 8 hours (584 and 607 patients, respectively). Comparable efficacy was demonstrated between the every 12 hours and every 8 hours dosing regimens.

There was no significant difference in the percentage of adverse events in each group. The most frequently reported adverse event was diarrhea; incidence rates were similar for the 875 mg/125 mg every 12 hours and 500 mg/125 mg every 8 hours dosing regimens (15% and 14%, respectively); however, there was a statistically significant difference (p less than 0.05) in rates of severe diarrhea or withdrawals with diarrhea between the regimens: 1% for 875 mg/125 mg every 12 hours regimen versus 2% for the 500 mg/125 mg every 8 hours regimen.

In one of these pivotal trials, patients with either pyelonephritis (n equals 361) or a complicated urinary tract infection (i.e., patients with abnormalities of the urinary tract that predispose to relapse of bacteriuria following eradication, n equals 268) were randomized (1:1) to receive either 875 mg/125mg tablets of Amoxicillin and Clavulanate Potassium every 12 hours (n equals 308) or 500 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium every 8 hours (n equals 321). The number of bacteriologically evaluable patients was comparable between the two dosing regimens.

Amoxicillin and Clavulanate Potassium produced comparable bacteriological success rates in patients assessed 2 to 4 days immediately following end of therapy. The bacteriologic efficacy rates were comparable at one of the follow‑up visits (5 to 9 days post‑therapy) and at a late post‑therapy visit (in the majority of cases, this was 2 to 4 weeks post-therapy), as seen in Table 8. Table 8: Bacteriologic efficacy rates for Amoxicillin and Clavulanate Potassium Time Post Therapy 875 mg every 12 hours % (n) 500 mg every 8 hours % (n) 2 to 4 days 81% (58) 80% (54) 5 to 9 days 58% (41) 52% (52) 2 to 4 weeks 52% (101) 55% (104) As noted before, though there was no significant difference in the percentage of adverse events in each group, there was a statistically significant difference in rates of severe diarrhea or withdrawals with diarrhea between the regimens.

14.2Acute Bacterial Otitis Media and Diarrhea in Pediatric Patients One US/Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of Amoxicillin and Clavulanate Potassium for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of Amoxicillin and Clavulanate Potassium for 10 days in the treatment of acute otitis media. Only the suspension formulations were used in this trial. A total of 575 pediatric patients (aged 2 months to 12 years) were enrolled, with an even distribution among the 2 treatment groups and a comparable number of patients were evaluable (i.e., greater than or equal to 84%) per treatment group.

Otitis media‑specific criteria were required for eligibility and a strong correlation was found at the end of therapy and follow‑up between these criteria and physician assessment of clinical response. The clinical efficacy rates at the end of therapy visit (defined as 2 to 4 days after the completion of therapy) and at the follow‑up visit (defined as 22 to 28 days post‑completion of therapy) were comparable for the 2 treatment groups, with the following cure rates obtained for the evaluable patients: At end of therapy, 87% (n equals 265) and 82% (n equals 260) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively.

At follow‑up, 67% (n equals 249) and 69% (n equals 243) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively. Diarrhea… [Excerpted — this section continues on DailyMed.]

🧪 Nonclinical Toxicology 205 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long‑term studies in animals have not been performed to evaluate carcinogenic potential. Amoxicillin and Clavulanate Potassium (4:1 ratio formulation of amoxicillin:clavulanate) was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin and Clavulanate Potassium was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival.

Amoxicillin and Clavulanate Potassium was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses of up to 1,200 mg/kg/day was found to have no effect on fertility and reproductive performance in rats.

Based on body surface area, this dose of amoxicillin is approximately 4 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, the dose multiple is approximately 9 times higher than the maximum recommended adult human oral dose (125 mg every 8 hours), also based on body surface area.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 202 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long‑term studies in animals have not been performed to evaluate carcinogenic potential. Amoxicillin and Clavulanate Potassium (4:1 ratio formulation of amoxicillin:clavulanate) was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin and Clavulanate Potassium was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival.

Amoxicillin and Clavulanate Potassium was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses of up to 1,200 mg/kg/day was found to have no effect on fertility and reproductive performance in rats.

Based on body surface area, this dose of amoxicillin is approximately 4 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, the dose multiple is approximately 9 times higher than the maximum recommended adult human oral dose (125 mg every 8 hours), also based on body surface area.

📚 References 31 words ▾

15 REFERENCES Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30: 66‑67.

📄 Recent Major Changes 11 words ▾

Warnings and Precautions, Drug-Induced Enterocolitis Syndrome (DIES) ( 5 .3) 05/2024

📄 Package Label / Principal Display Panel ~2 min read ▾

Bottle Label (20s) 875mg/125mg Tablets NDC 81964- 221 -14 AMOXICILLIN AND CLAVULANATE POTASSIUM TABLETS, USP 875 mg/125 mg AMOXICILLIN, 875 mg as the trihydrate, and CLAVULANIC ACID, 125 mg (equivalent to 149 mg of clavulanate potassium) Rx only 20 Tablets U S ANTIBIOTICS 20s 875mg

Bottle Label (100s) 875mg/125mg Tablets NDC 81964- 221 -01 AMOXICILLIN AND CLAVULANATE POTASSIUM TABLETS, USP 875 mg/125 mg AMOXICILLIN, 875 mg as the trihydrate, and CLAVULANIC ACID, 125 mg (equivalent to 149 mg of clavulanate potassium) 100 Tablets Rx only U S ANTIBIOTICS label (100s) 875mg/125mg Tablets

Bottle Label (75 mL) 125mg/31.25mg Oral Suspension NDC 81964- 212 -01 125 mg/31.25 mg per 5 mL AMOXICILLIN AND CLAVULANATE POTASSIUM for oral suspension, USP When reconstituted, each 5 mL contains: AMOXICILLIN, 125 mg as the trihydrate, and CLAVULANIC ACID, 31.25 mg (equivalent to 37.23 mg of clavulanate potassium) 75 mL (when reconstituted) U S ANTIBIOTICS Rx only Bottle Label (75 mL) 125mg/31.25mg

Bottle Label (100 mL) 125mg/31.25mg for Oral Suspension NDC 81964- 212 -03 125 mg/31.25 mg per 5 mL AMOXICILLIN AND CLAVULANATE POTASSIUM for oral suspension, USP When reconstituted, each 5 mL contains: AMOXICILLIN, 125 mg as the trihydrate, and CLAVULANIC ACID, 31.25 mg (equivalent to 37.23 mg of clavulanate potassium) 100 mL (when reconstituted) U S ANTIBIOTICS Rx only Bottle Label (100 mL) 125mg/31.25mg

Bottle Label (150 mL) 125mg/31.25mg for Oral Suspension NDC 81964- 212 -05 125 mg/31.25 mg per 5 mL AMOXICILLIN AND CLAVULANATE POTASSIUM for oral suspension, USP When reconstituted, each 5 mL contains: AMOXICILLIN, 125 mg as the trihydrate, and CLAVULANIC ACID, 31.25 mg (equivalent to 37.23 mg of clavulanate potassium) 150 mL (when reconstituted) U S ANTIBIOTICS Rx only Bottle Label (150 mL) 125mg/31.25mg

Bottle Label (75 mL) 250mg/62.5mg for Oral Suspension NDC 81964- 204 -07 250 mg/62.5 mg per 5 mL AMOXICILLIN AND CLAVULANATE POTASSIUM for oral suspension, USP When reconstituted, each 5 mL contains: AMOXICILLIN, 250 mg as the trihydrate, and CLAVULANIC ACID, 62.5 mg (equivalent to 74.5 mg of clavulanate potassium) 75 mL (when reconstituted) U S ANTIBIOTICS Rx only Bottle Label (75 mL) 250mg/62.5mg

Bottle Label (100 mL) 250mg/62.5mg for Oral Suspension NDC 81964- 204 -10 250 mg/62.5 mg per 5 mL AMOXICILLIN AND CLAVULANATE POTASSIUM for oral suspension, USP When reconstituted, each 5 mL contains: AMOXICILLIN, 250 mg as the trihydrate, and CLAVULANIC ACID, 62.5 mg (equivalent to 74.5 mg of clavulanate potassium) 100 mL (when reconstituted) U S ANTIBIOTICS Rx only Bottle Label (100 mL) 250mg/62.5mg

Bottle Label (150 mL) 250mg/62.5mg for Oral Suspension NDC 81964- 204 -15 250 mg/62.5 mg per 5 mL AMOXICILLIN AND CLAVULANATE POTASSIUM for oral suspension, USP When reconstituted, each 5 mL contains: AMOXICILLIN, 250 mg as the trihydrate, and CLAVULANIC ACID, 62.5 mg (equivalent to 74.5 mg of clavulanate potassium) 150 mL (when reconstituted) U S ANTIBIOTICS Rx only Bottle Label (150 mL) 250mg/62.5mg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
5.7K
Units reimbursed last 4 qtrs
825.8K
Gross reimbursed last 4 qtrs
$371.4K
Avg / prescription
$65.08
Avg / unit
$0.4497
Latest quarter Q1 2026
1.3KRx
Medicaid pays / mL
$0.4497
gross reimbursed
vs
NADAC / mL
$0.4293
acquisition cost
=
Spread
+$0.0204
+5% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
23% FFS 77% MCO
Fee-for-service · 1,287 Rx Managed care · 4,419 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 10,500 units · 134 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 17,700 units · 176 per 100k residents MI New York: 69,125 units · 353 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 3,100 units · 73.2 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 9,515 units · 75.8 per 100k residents IL Indiana: no data reported IN Ohio: 19,700 units · 167 per 100k residents OH Pennsylvania: 4,600 units · 35.5 per 100k residents PA New Jersey: 24,205 units · 261 per 100k residents NJ Massachusetts: no data reported MA California: 45,110 units · 116 per 100k residents CA Utah: no data reported UT Colorado: 3,400 units · 57.8 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 20,302 units · 449 per 100k residents KY West Virginia: 6,100 units · 345 per 100k residents WV Virginia: 4,100 units · 47.0 per 100k residents VA Maryland: 1,100 units · 17.8 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 5,000 units · 67.3 per 100k residents AZ New Mexico: 2,900 units · 137 per 100k residents NM Kansas: 1,000 units · 34.0 per 100k residents KS Arkansas: 16,605 units · 541 per 100k residents AR Tennessee: 12,675 units · 178 per 100k residents TN North Carolina: 13,753 units · 127 per 100k residents NC South Carolina: 7,800 units · 145 per 100k residents SC Delaware: no data reported DE Oklahoma: 27,400 units · 676 per 100k residents OK Louisiana: 37,450 units · 819 per 100k residents LA Mississippi: 20,770 units · 706 per 100k residents MS Alabama: 17,825 units · 349 per 100k residents AL Georgia: 37,200 units · 337 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 310,250 units · 1,017 per 100k residents TX Florida: 70,500 units · 312 per 100k residents FL
Units reimbursed · per 100k residents
17.81,017
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Texas 1,017 /100k
2 Louisiana 819 /100k
3 Mississippi 706 /100k
4 Oklahoma 676 /100k
5 Arkansas 541 /100k
6 Kentucky 449 /100k
7 New York 353 /100k
8 Alabama 349 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 ml this page81964-0204-10 5,706 Rx · $371,371
75 ml81964-0204-07 2,829 Rx · $153,158
150 ml81964-0204-15 1,925 Rx · $163,332
Drug total (last 4 qtrs): 10,460 Rx · 1,533,315 units · $687,860 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Amoxicillin and Clavulanate Potassium — the ingredient across all brands.

Top reported reactions

Diarrhoea1,880
Drug Hypersensitivity1,818
Nausea1,436
Dyspnoea1,404
Pyrexia1,397
Fatigue1,280
Pneumonia1,192

Age at onset

Neonate22
Infant18
Child89
Adolescent65
Adult1,981
Elderly1,579

Reporter sex

27,016 reports
Male · 43%
Female · 57%
Unknown · 0%

Serious outcomes

Hospitalization13,275
Death2,605
Life-threatening1,838
Disabling591
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 2,415 612
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.